ArticleResearch (Washington, D.C.)2022
Integrated Au-Nanoroded Biosensing and Regulating Platform for Photothermal Therapy of Bradyarrhythmia.
Article in Research (Washington, D.C.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Integrated meta-analysis and network pharmacology analysis: evaluation of Zhigancao decoction as treatment for diabetic cardiomyopathy.Frontiers in cardiovascular medicine · 2025Pooled it
- Integrated precise temperature regulation and electrophysiology sensing system for nanoplasmonic photothermal cardiac bradyarrhythmia therapy.Microsystems & nanoengineering · 2026Article
- Endogenous and exogenous stimuli-driven intelligent nanocarriers: emerging strategies for the treatment of myocardial infarction.Journal of nanobiotechnology · 2026Review
- Cardiac action potential generation mechanisms via an intramembrane photoswitch. A simulation study.Biophysical journal · 2025Article
- Optically Active, Paper-Based Scaffolds for 3D Cardiac Pacing.ACS applied materials & interfaces · 2024Article
- Lignin containing cellulose nanofiber/AgRSC advances · 2024Article
- Safety and efficacy of cardioneuroablation for vagal bradycardia in a single arm prospective study.Scientific reports · 2024Article
- The clinical prospects and challenges of photothermal nanomaterials in myocardium recovery after myocardial infarction.Frontiers in bioengineering and biotechnology · 2024Review
- Light-triggered cardiac microphysiological model.APL bioengineering · 2023Article
- Optical modulation of excitation-contraction coupling in human-induced pluripotent stem cell-derived cardiomyocytes.iScience · 2023Article
- Black Phosphorus for Photonic Integrated Circuits.Research (Washington, D.C.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bradyarrhythmia is a kind of cardiovascular disease caused by dysregulation of cardiomyocytes, which seriously threatens human life. Currently, treatment strategies of bradyarrhythmia mainly include drug therapy, surgery, or implantable cardioverter defibrillators, but these strategies are limited by drug side effect, surgical trauma, and instability of implanted devices. Here, we developed an integrated Au-nanoroded biosensing and regulating platform to investigate the photothermal therapy of cardiac bradyarrhythmia
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.